Avance Biosciences, Inc.

Founded in 2002, CELPROGEN is a biotechnology company, with over 5000 products in the market, focused on developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media with specific ECM’s, are manufactured and produced in the United States of America.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, In-vitro diagnostics and academic partnership for drug discovery.

It has 3 divisions:

• Therapeutic Division: Focused on Drug Discovery efforts to develop Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Oncology,Renal and Metabolic disorders.
• Life Science Division: Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for life science academic and pharmaceutical communities.
• Device Division: Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and In-vitro diagnostics Industries.

EpigenDx was incorporated in 2006 as a genomic and epigenomic research company specializing in disease biomarker discovery, validation and molecular diagnosis, with an unmatched expertise in the field of DNA methylation analysis.

EpigenDx provides superior products and laboratory services for scientific researchers from academic, government and industrial communities from all over the world. Our commitment to quality reflects our desire and dedication to provide the best products and services to our customers. EpigenDx has extensive knowledge and expertise in Pyrosequencing, bisulfite sequencing, and various epigenomic research analysis techniques and methods stemming from our years of experience in the industry.

EpigenDx Lab Services include:
DNA Methylation
- Bisulfite Pyrosequencing: determine loci specific methylation and global methylation levels individual CpGs sites
- Targeted MethylSeq: determine methylation levels in multiple targeted regions at base pair resolution
Expression Analysis
- Gene and miRNA profiling using Affymetrix Gene Chip arrays
Mutation & SNP Analysis
- Quantative mutation analysis using Pyrosequencing for minor allele detection, allele specific expression
- 1.8 million SNPs and copy number changes using Affymetrix 6.0 Array

EpigenDx products include:
DNA Methylation Controls: low and high methylated genomic DNA for studying human, mouse, rat genes
Validated loci specific DNA methylation assays for multiple platforms including bisulfite sequencing, bisulfite Pyrosequencing, and realtime based PCR analysis. All assays are validated for PCR bias or preferential amplification.
Methylation Panels including Stem Cell Panel, Cancer Panel, Immunology Panel, and CNS Panel. They are designed for bisulfite sequencing analysis using either Pyrosequencing or NGS platforms.

Geneuity provides innovative specialized laboratory testing for preclinical through Phase lV clinical trials to promote the safety and efficacy of experimental therapeutics and new diagnostic assays. Geneuity has expertise in genomics, custom assay design, method development and validation. We provide scientific & clinical consultation to pharmaceutical and diagnostics companies as well CROs and IVD kit manufacturers.

Geneuity maintains a complete catalogue of analytically validated assays for DNA/RNA, biomarker, and proteomic analyses including multiplex PCR, gene expression, cytokine/protein multiplexing, ELISA/immunoassays, DNA sequencing, MDx, flow cytometry, cytogenetics/FISH, Immunohistochemistry, Cellsearch Circulating Tumor Cell (CTC & CEC) analysis, cell culture, anatomic pathology, toxicology and routine biochemistry.

Geneuity is a division of Molecular Pathology Laboratory Network, Inc. (MPLN), a privately held molecular diagnostic laboratory in business for over 20 years.

Geneuity & MPLN are GLP compliant, certified under Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP) and licensed by the states of NY, FL, TN and MD.

Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.

With over 40 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings.

Our operations are strategically located in:
Lincoln, Nebraska (Corporate Headquarters)
Philadelphia, Pennsylvania
Phoenix, Arizona
Belfast, Northern Ireland,UK
Zurich, Switzerland
Richmond, Virginia
Montreal, Quebec, Canada

For more information, visit: www.celerion.com

Marin Biologic blends the fields of cell biology, immunology, molecular biology and biochemistry to tackle complex projects in an innovative and timely manner. We simultaneously utilize our in-depth scientific expertise to collectively approach projects to complement our client’s approach and meet the client’s needs.

Marin Biologic is a woman PhD owned and managed Contract Research Laboratory which specializes in the research, pre-clinical and clinical development and validation of cell based assays and immunoassays for biotech and pharmaceutical companies in Phase I/II or Phase III stages. Our unique approach to collaboration encourages scientists to talk to scientists to create better science.

We are compliant with U.S. FDA cGMP/GLP standards as well as ICH for all levels of clinical development. We employ these standards that are phase appropriate for your clinical development or research.

CEO and President Tania Weiss PhD founded Marin Biologic Laboratories in 1995 to be able to apply her enthusiasm for good scientific process to a broad array of client projects. As a result, the client list as well as the project list is very diverse over the history of the Company. Marin Biologic seeks out and attracts interesting and different scientific opportunities, which puts them at the forefront of scientific development.

Our Lab is located in Novato, California, halfway between San Francisco and the Napa and Sonoma Valleys.

Peter Ralph. PhD, VP Science, peter@marinbio.com
Tania Weiss, PhD, CEO, tania@marinbio.com

415 883-8000
Visit: www.marinbio.com to connect with us, or ask us a question.